Sep. 9 at 2:38 PM
@Dirtymartini66 @telomerase He's a loser who sold SLS too early and now is bitter. Reality is that
$GLSI has some potential issues with its drug design that
$SLS and GPS doesn't have.
Importantly, GLSI has literally only
$8MM in cash and just expanded their phase 3 trial but a ton (hmm, wonder why). So there's a guarantee of dilution, probably more than one time, in their future.
